Vincerx Pharma (VINC) Set to Announce Earnings on Tuesday

Vincerx Pharma (NASDAQ:VINCGet Free Report) will post its quarterly earnings results on Tuesday, March 26th.

Vincerx Pharma Stock Performance

Vincerx Pharma stock opened at $5.02 on Monday. The firm has a market cap of $107.33 million, a PE ratio of -2.17 and a beta of 1.03. Vincerx Pharma has a twelve month low of $0.61 and a twelve month high of $9.37. The firm’s 50 day moving average price is $3.26 and its two-hundred day moving average price is $1.73.

Institutional Trading of Vincerx Pharma

Large investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP grew its position in Vincerx Pharma by 56.1% in the first quarter. ExodusPoint Capital Management LP now owns 391,748 shares of the company’s stock worth $407,000 after acquiring an additional 140,753 shares in the last quarter. Millennium Management LLC grew its position in Vincerx Pharma by 562.4% in the second quarter. Millennium Management LLC now owns 306,598 shares of the company’s stock worth $405,000 after acquiring an additional 260,310 shares in the last quarter. Bank of Montreal Can bought a new stake in Vincerx Pharma in the first quarter worth approximately $332,000. Tejara Capital Ltd bought a new stake in Vincerx Pharma in the fourth quarter worth approximately $317,000. Finally, Citadel Advisors LLC grew its position in Vincerx Pharma by 16.9% in the fourth quarter. Citadel Advisors LLC now owns 197,359 shares of the company’s stock worth $233,000 after acquiring an additional 28,530 shares in the last quarter. 44.02% of the stock is owned by institutional investors.

About Vincerx Pharma

(Get Free Report)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.

Further Reading

Earnings History for Vincerx Pharma (NASDAQ:VINC)

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.